%201.svg){kind=small}
Associate Director, US Oncology Marketing, Patient Experience Strategy Lead, Intismeran Autogene
MSD
North Wales, PA (Remote)
$157K/yr - $247K/yrIn-houseFull-timeSenior level5+ years exp.
4 days ago
Associate Director, Marketing
Cambridge, MA (Hybrid)
$177K/yr – $240K/yrMid Level7+ years expOther
Posted 4 days ago
Job Summary
Original Job Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease. Please review our social media guidelines at: https://akebia.com/social-media-guidelines/
Marketing team
10
Employees
273
Headquarters
Cambridge, Massachusetts, USA
Founded
2007
Employee Sentiment
Overall Rating
3.4 / 5
Recommend to a Friend
62%
CEO Approval
90%
Source: Glassdoor
Traffic Signals
Monthly Visitors
9.1K
Monthly Google Ads Budget
$0.0
Traffic Source Mix
Search
42.4%
Direct
43.2%
Referral
5.8%
Social
7.3%
Paid
1.1%
Headcount Trend
Current headcount: ~273
Funding
Total Funding
$442.5M
Last Raise
2 years ago
Last Raise Amount
$37.0M
- 2024-01-30Post IPO Debt • $37.0M
- 2020-05-11Post IPO Equity • $151.8M
- 2019-11-12Post IPO Debt • $100.0M
Recent News
newser.com
Is Akebia Therapeutics Inc. stock cheap at current valuation
Nov 19, 2025
newser.com
Tools to assess Akebia Therapeutics Inc.’s risk profile - Trade Analysis Summary & Technical Confirmation Trade Alerts
Nov 18, 2025
investing.com
Akebia Therapeutics amends license agreement with Medice for Vafseo supply
Nov 17, 2025
TipRanks
Akebia Therapeutics Amends License Agreement with MEDICE
Nov 17, 2025
simplywall.st
Why Akebia Therapeutics (AKBA) Is Up After Strong Q3 Earnings and Promising Vafseo Kidney Data
Nov 13, 2025
Yahoo Finance
Implied Volatility Surging for Akebia Therapeutics Stock Options
Nov 13, 2025
Yahoo Finance
Akebia Therapeutics (AKBA): Valuation Insights Following Q3 Profit Surge and Positive Vafseo Clinical Update
Nov 12, 2025
Yahoo Finance
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nov 11, 2025
simplywall.st
A Look at Akebia Therapeutics (AKBA) Valuation Following Q3 Profit and New Vafseo Clinical Data
Nov 11, 2025
Yahoo Finance
Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
Nov 10, 2025
GlobeNewswire
Akebia Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2025
Stock Titan
Akebia (NASDAQ: AKBA) to present at Guggenheim and Jefferies in November
Nov 4, 2025
simplywall.st
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Nov 4, 2025
Sahm
Akebia Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2025
MarketBeat
Q3 EPS Estimate for Akebia Therapeutics Increased by Analyst
Nov 3, 2025
Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2025
MarketBeat
Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday
Oct 31, 2025
Stock Titan
Akebia Therapeutics (Nasdaq: AKBA) schedules Nov. 10, 8 a.m. EST results call
Oct 30, 2025
GuruFocus
Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News
Oct 30, 2025
MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap Down - Here's Why
Oct 30, 2025
Yahoo Finance
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients
Oct 30, 2025
Stocktwits
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion
Oct 29, 2025
Fierce Pharma
Akebia scraps plan for Vafseo trial after discussions with FDA
Oct 29, 2025
investing.com
Akebia stock tumbles after FDA meeting on vadadustat trial design
Oct 29, 2025
The Pharma Letter
FDA setback prompts Akebia to give up on broader Vafseo label
Oct 29, 2025
The Business Journals
Akebia stock plunges as kidney drug expansion plans scrapped
Oct 29, 2025
Seeking Alpha
Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core (NASDAQ:AKBA)
Oct 29, 2025
Citeline News & Insights
Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs
Oct 29, 2025
Stock Titan
Akebia (NASDAQ: AKBA) to forgo broad Vafseo label in NDD‑CKD post FDA Type C meeting
Oct 28, 2025
TipRanks
Akebia Therapeutics Halts VALOR Trial for Vadadustat
Oct 28, 2025
Yahoo Finance
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
Oct 28, 2025
FirstWord Pharma
Akebia ditches plans for Vafseo label expansion
Oct 28, 2025
GuruFocus
Akebia Therapeutics (AKBA) Halts Expansion Plans for Vafseo
Oct 28, 2025
Seeking Alpha
Akebia plummets as it abandons Vafseo for non-dialysis patients
Oct 28, 2025
TipRanks
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications
Oct 27, 2025
newser.com
Comparing Akebia Therapeutics Inc. in custom built stock radars - July 2025 Pullbacks & Weekly High Potential Stock Alerts
Oct 24, 2025
newser.com
Can Akebia Therapeutics Inc. (AX9) stock deliver strong annual returns - Weekly Profit Report & Community Trade Idea Sharing
Oct 24, 2025
newser.com
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current price - Earnings Beat & Weekly High Conviction Trade Ideas
Oct 24, 2025
newser.com
How rising interest rates impact Akebia Therapeutics Inc. stock - Bull Run & Free Safe Entry Trade Signal Reports
Oct 24, 2025
newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth funds - Stock Surge & Weekly High Return Stock Opportunities
Oct 23, 2025
newser.com
How forex fluctuations impact Akebia Therapeutics Inc. (AX9) stock - Risk Management & Daily Growth Stock Tips
Oct 22, 2025
newser.com
Can Akebia Therapeutics Inc. (AX9) stock deliver strong annual returns - Portfolio Value Summary & Low Risk High Reward Trade Ideas
Oct 21, 2025
newser.com
Is this a good reentry point in Akebia Therapeutics Inc. - Trend Reversal & AI Enhanced Execution Alerts
Oct 20, 2025
newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth funds - July 2025 Update & Free Long-Term Investment Growth Plans
Oct 20, 2025
Quiver Quantitative
Akebia Therapeutics to Present New Data on Vafseo® at ASN Kidney Week 2025
Oct 20, 2025
GlobeNewswire
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Oct 20, 2025
Stock Titan
Five Presentations: Akebia Showcases Vafseo Real-World, Dosing & Win-Odds Data at ASN Kidney Week
Oct 20, 2025
newser.com
How Akebia Therapeutics Inc. stock performs in interest rate cycles - 2025 AllTime Highs & Intraday High Probability Alerts
Oct 18, 2025
nchmf.gov.vn
Will Akebia Therapeutics Inc. stock see insider buying - 2025 Key Highlights & High Conviction Trade Alerts
Oct 18, 2025
nchmf.gov.vn
Support Test: Is Akebia Therapeutics Inc. stock dividend yield sustainable - July 2025 Outlook & Precise Swing Trade Entry Alerts
Oct 18, 2025
nchmf.gov.vn
How Akebia Therapeutics Inc. stock reacts to inflationary pressures - July 2025 Rallies & Free Accurate Trade Setup Notifications
Oct 18, 2025
nchmf.gov.vn
Will Akebia Therapeutics Inc. stock see insider buying - Market Sentiment Summary & Consistent Profit Trading Strategies
Oct 18, 2025
simplywall.st
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook
Oct 7, 2025
Sahm
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook
Oct 7, 2025
Stock Titan
204,163 Stock Options: Akebia Therapeutics Awards New Employee Grants with 4-Year Vesting Terms
Oct 1, 2025
GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2025
simplywall.st
Retail investors who have a significant stake must be disappointed along with institutions after Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) market cap dropped by US$50m
Sep 11, 2025
Investing.com
Akebia at H.C. Wainwright: Strategic Growth in Anemia Treatment
Sep 8, 2025
Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43%
Sep 6, 2025
MarketScreener
Transcript : Akebia Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 08
Sep 5, 2025
Investing.com
Akebia at Wells Fargo Conference: Strategic Growth in Healthcare
Sep 4, 2025
BioSpace
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 2, 2025
Sep 3, 2025
GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025
Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025
Akebia Therapeutics, Inc.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025
Seeking Alpha
Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection
Aug 28, 2025
Stock Titan
Kidney Disease Biotech Akebia Therapeutics Set for Key Presentations at Major September Conferences
Aug 28, 2025
Yahoo Finance
Akebia Therapeutics to Present at Upcoming Investor Conferences
Aug 28, 2025
Akebia Therapeutics, Inc.
Akebia Therapeutics to Present at Upcoming Investor Conferences
Aug 28, 2025
EIN Presswire
Dialysis Induced Anemia Treatment Market Poised for Strong Growth, Doubling to USD 4.5 Billion by 2035
Aug 26, 2025
BioSpace
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 22, 2025
Yahoo Finance
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 21, 2025
Akebia Therapeutics, Inc.
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 21, 2025
thefly.com
Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics
Aug 21, 2025
Morningstar.com
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 21, 2025
Yahoo Finance
Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth
Aug 19, 2025
TipRanks
Akebia Therapeutics Reports Record Revenue and Strategic Growth
Aug 12, 2025
Yahoo Finance
The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 10, 2025
simplywall.st
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
Aug 10, 2025
Yahoo Finance
Akebia Therapeutics Second Quarter 2025 Earnings: EPS: US$0.001 (vs US$0.041 loss in 2Q 2024)
Aug 9, 2025
TipRanks
Akebia Therapeutics Reports Strong Q2 2025 Growth
Aug 7, 2025
Yahoo Finance
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Aug 7, 2025
Investing.com
Earnings call transcript: Akebia Ther Q2 2025 earnings miss, stock drops
Aug 7, 2025
GuruFocus
Akebia Therapeutics Inc Q2 2025 Earnings: Revenue Surges to $62.
Aug 7, 2025
TradingView
Akebia Therapeutics, Inc. SEC 10-Q Report
Aug 7, 2025
MarketScreener
Akebia Therapeutics Q2 revenue smashes expectations
Aug 7, 2025
Akebia Therapeutics, Inc.
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 7, 2025
Yahoo Finance
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Aug 6, 2025
Morningstar.com
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Aug 6, 2025
GlobeNewswire
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
Aug 4, 2025
Yahoo Finance
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
Aug 4, 2025
BioSpace
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 1, 2025
Aug 3, 2025
Akebia Therapeutics, Inc.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2025
Stock Titan
Akebia Therapeutics Earnings: Q2 2025 Financial Results Coming August 7 - Key Details for Investors
Jul 31, 2025
Yahoo Finance
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Jul 31, 2025
Akebia Therapeutics, Inc.
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Jul 31, 2025
StocksToTrade
Akebia Therapeutics Stock Dips Amid Financial Challenges
Jul 25, 2025
Yahoo Finance
H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy
Jul 25, 2025
Yahoo Finance
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share
Jul 22, 2025
Yahoo Finance
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
Jul 16, 2025
